P-78 Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies

Cancer Patients ◽

Pooled Analysis ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Load ◽

Tumour Shrinkage ◽

Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdz155.199 ◽

2019 ◽

Vol 30 ◽

pp. iv54

Author(s):

A. Kr ◽

S.S. P ◽

R. Kumar C

Keyword(s):

Colorectal Cancer ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage ◽

The Impact

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-017-2534-z ◽

2017 ◽

Vol 144 (2) ◽

pp. 321-335 ◽

Cited By ~ 12

Author(s):

Julien Taieb ◽

Fernando Rivera ◽

Salvatore Siena ◽

Meinolf Karthaus ◽

Manuel Valladares-Ayerbes ◽

...

Keyword(s):

Colorectal Cancer ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage ◽

The Impact

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-018-2591-y ◽

2018 ◽

Vol 144 (4) ◽

pp. 795-797

Author(s):

Julien Taieb ◽

Fernando Rivera ◽

Salvatore Siena ◽

Meinolf Karthaus ◽

Manuel Valladares-Ayerbes ◽

...

Keyword(s):

Colorectal Cancer ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage ◽

The Impact

Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study

Annals of Oncology ◽

10.1093/annonc/mdz246.049 ◽

2019 ◽

Vol 30 ◽

pp. v216

Author(s):

A. Sartore-Bianchi ◽

M. Peeters ◽

M. Geissler ◽

J. Taieb ◽

P. García-Alfonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Retrospective Analysis ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies

British Journal of Cancer ◽

10.1038/s41416-021-01483-x ◽

2021 ◽

Author(s):

Roberto Moretto ◽

Daniele Rossini ◽

Veronica Conca ◽

Sara Lonardi ◽

Cosimo Rasola ◽

...

Keyword(s):

Colorectal Cancer ◽

Disease Progression ◽

Cancer Patients ◽

Induction Therapy ◽

Pooled Analysis ◽

First Line ◽

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Annals of Oncology ◽

10.1093/annonc/mdw335.14 ◽

2016 ◽

Vol 27 ◽

pp. iv43

Author(s):

D. Rossini ◽

M. Casagrande ◽

R. Moretto ◽

F. Loupakis ◽

C. Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Line Treatment ◽

Targeted Agents ◽

First Line ◽

Safety And Efficacy ◽

Colorectal Cancer Patients ◽

First Line Treatment

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

Annals of Oncology ◽

10.1016/j.annonc.2019.10.005 ◽

2020 ◽

Vol 31 (1) ◽

pp. 88-95 ◽

Cited By ~ 5

Author(s):

T. Yoshino ◽

J.M. Cleary ◽

E. Van Cutsem ◽

R.J. Mayer ◽

A. Ohtsu ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Survival Outcomes ◽

Abstract 2619: Genetic landscape of KRAS-NRAS-BRAF-PIK3CA wild type metastatic colorectal cancer patients enrolled in the CAPRI clinical trial

10.1158/1538-7445.am2018-2619 ◽

2018 ◽

Cited By ~ 1

Author(s):

Anna Maria Rachiglio ◽

Matilde Lambiase ◽

Francesca Fenizia ◽

Alessia Iannaccone ◽

Cristin Roma ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Trial ◽

Cancer Patients ◽

Wild Type ◽

Genetic Landscape ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

British Journal of Cancer ◽

10.1038/s41416-019-0537-z ◽

2019 ◽

Vol 121 (5) ◽

pp. 378-383 ◽

Cited By ~ 1

Author(s):

Elena Elez ◽

Carles Pericay ◽

Manuel Valladares-Ayerbes ◽

Inmaculada Bando ◽

Maria Jose Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Salvage Therapy ◽

Phase 2 ◽

Wild Type ◽

Exon 2 ◽

Phase 2 Study ◽

Colorectal Cancer Patients ◽

Kras Exon